Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$8.90 USD
-0.44 (-4.71%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $8.91 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Corbus Pharmaceuticals Holdings, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
CRBP 8.90 -0.44(-4.71%)
Will CRBP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRBP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRBP
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?
CRBP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold?
3 Unconventional Cannabis Stocks to Watch in 2025
Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High?
Other News for CRBP
Corbus Pharmaceuticals (CRBP) Gears Up for Pivotal Data Presentations in Late 2025
Corbus Pharmaceuticals GAAP EPS of -$1.44 misses by $0.08
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate ...
Corbus Pharmaceuticals reports Q2 EPS ($1.44), consensus ($1.33)
CRBP: B. Riley Maintains Buy Rating with Promising Drug Potential